Arrestin domain-containing 3 (Arrdc3) modulates insulin action and glucose metabolism in liver
- 24 March 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (12), 6733-6740
- https://doi.org/10.1073/pnas.1922370117
Abstract
Insulin action in the liver is critical for glucose homeostasis through regulation of glycogen synthesis and glucose output. Arrestin domain-containing 3 (Arrdc3) is a member of the alpha-arrestin family previously linked to human obesity. Here, we show that Arrdc3 is differentially regulated by insulin in vivo in mice undergoing euglycemic-hyperinsulinemic clamps, being highly up-regulated in liver and down-regulated in muscle and fat. Mice with liver-specific knockout (KO) of the insulin receptor (IR) have a 50% reduction in Arrdc3 messenger RNA, while, conversely, mice with liver-specific KO of Arrdc3 (L-Arrdc3 KO) have increased IR protein in plasma membrane. This leads to increased hepatic insulin sensitivity with increased phosphorylation of FOXO1, reduced expression of PEPCK, and increased glucokinase expression resulting in reduced hepatic glucose production and increased hepatic glycogen accumulation. These effects are due to interaction of ARRDC3 with IR resulting in phosphorylation of ARRDC3 on a conserved tyrosine (Y382) in the carboxyl-terminal domain. Thus, Arrdc3 is an insulin target gene, and ARRDC3 protein directly interacts with IR to serve as a feedback regulator of insulin action in control of liver metabolism.Funding Information
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK031036)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK033201)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (5U2C-DK093000)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK107396)
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F32DK105682)
This publication has 36 references indexed in Scilit:
- An expanded family of arrestins regulate metabolismTrends in Endocrinology & Metabolism, 2012
- Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1Nature Medicine, 2012
- The Arrestin Domain-Containing 3 Protein Regulates Body Mass and Energy ExpenditureCell Metabolism, 2011
- ARRDC3 suppresses breast cancer progression by negatively regulating integrin β4Oncogene, 2010
- Deletion of the α-Arrestin Protein Txnip in Mice Promotes Adiposity and Adipogenesis While Preserving Insulin SensitivityDiabetes, 2010
- Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposalAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Thioredoxin-independent Regulation of Metabolism by the α-Arrestin ProteinsOnline Journal of Public Health Informatics, 2009
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences of the United States of America, 2008
- TXNIP Regulates Peripheral Glucose Metabolism in HumansPLoS Medicine, 2007
- Insulin signalling and the regulation of glucose and lipid metabolismNature, 2001